With 3.47 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.23 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.99 whereas the lowest price it dropped to was $1.91. The 52-week range on AKBA shows that it touched its highest point at $2.48 and its lowest point at $0.80 during that stretch. It currently has a 1-year price target of $7.17. Beta for the stock currently stands at 0.85.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKBA was up-trending over the past week, with a rise of 4.04%, but this was down by -8.10% over a month. Three-month performance dropped to -5.85% while six-month performance rose 35.92%. The stock gained 31.29% in the past year, while it has gained 1.58% so far this year. A look at the trailing 12-month EPS for AKBA yields -0.22 with Next year EPS estimates of -0.16. For the next quarter, that number is -0.08. This implies an EPS growth rate of -9.12% for this year and 47.38% for next year.
Float and Shares Shorts:
At present, 211.54 million AKBA shares are outstanding with a float of 209.23 million shares on hand for trading. On 2025-02-28, short shares totaled 14.88 million, which was 681.9999999999999 higher than short shares on 1738281600. In addition to Mr. John P. Butler MBA as the firm’s CEO, President & Director, Dr. Steven Keith Burke M.D. serves as its Senior VP of Research & Development and Chief Medical Officer.
Institutional Ownership:
Through their ownership of 0.31282 of AKBA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AKBA reported revenue of $37428000.0 and operating income of -$12505000.0. The EBITDA in the recently reported quarter was -$3148000.0 and diluted EPS was -$0.1.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKBA since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKBA analysts setting a high price target of 10.0 and a low target of 4.0, the average target price over the next 12 months is 7.16667. Based on these targets, AKBA could surge 418.13% to reach the target high and rise by 107.25% to reach the target low. Reaching the average price target will result in a growth of 271.33% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.26479 being high and -$0.34627 being low. For AKBA, this leads to a yearly average estimate of -$0.30553. Based on analyst estimates, the high estimate for the next quarter is $0.0 and the low estimate is -$0.11. The average estimate for the next quarter is thus -$0.05.
